CAPZA1在非小细胞肺癌中的表达及临床价值
|
摘要
目的探讨CAPZA1在非小细胞肺癌(NSCLC)患者NSCLC组织中的表达情况及其与患者临床特征和预后的关系。方法采用免疫组织化学染色法检测CAPZA1在52例NSCLC患者NSCLC组织及其癌旁正常组织中的表达情况,分析不同临床特征NSCLC患者NSCLC组织中CAPZA1的表达情况及其与患者预后的关系。结果 NSCLC组织中CAPZA1低表达的比例明显高于癌旁正常组织(P﹤0.01)。不同性别、年龄、吸烟史、肿瘤直径、病理类型NSCLC患者NSCLC组织中的CAPZA1表达水平比较,差异均无统计学意义(P﹥0.05)。不同TNM分期、分化程度、淋巴结转移情况、脉管侵犯情况、Ki-67指数的NSCLC患者NSCLC组织中CAPZA1的表达水平比较,差异均有统计学意义(P﹤0.05)。Log-rank检验结果显示,CAPZA1高表达NSCLC患者的生存情况优于CAPZA1低表达NSCLC患者(P﹤0.05)。结论 CAPZA1在NSCLC组织中呈低表达,CAPZA1对判断NSCLC患者的病理特征与预后具有一定参考价值。
Objective To investigate the expression of CAPZA1 in the tissues of non-small cell lung cancer(NSCLC) and its relationship with clinical characteristics and prognosis. Method The expression of CAPZA1 in NSCLC tissues and adjacent normal tissues of 52 patients with NSCLC was detected by immunohistochemistry, besides,the expression of CAPZA1 in NSCLC patients with varying clinical characteristics were compared, moreover, the relationship between CAPZA1 expression and prognosis was analyzed statistically. Result The expression of CAPZA1 was obviously decreased in NSCLC tissues compared with that in adjacent normal tissues(P<0.01). There were no evident differences of CAPZA1 expression level among patients of different gender, age, smoking status, tumor size, or pathological type(P>0.05). The expression level of CAPZA1 was statistically associated with TNM stage, degree of differentiation,lymph node metastases, vascular invasion, and Ki-67 index, and the differences were statistically significant(P<0.05).The Log-rank test indicated that, better survival was observed in patients with high expression level of CAPZA1 compared with those with low CAPZA1 expression(P<0.05). Conclusion The expression of CAPZA1 is reduced in NSCLC tissues, and it is clinically valuable for evaluating the pathological features and prognosis of NSCLC patients.
Objective To investigate the expression of CAPZA1 in the tissues of non-small cell lung cancer(NSCLC) and its relationship with clinical characteristics and prognosis. Method The expression of CAPZA1 in NSCLC tissues and adjacent normal tissues of 52 patients with NSCLC was detected by immunohistochemistry, besides,the expression of CAPZA1 in NSCLC patients with varying clinical characteristics were compared, moreover, the relationship between CAPZA1 expression and prognosis was analyzed statistically. Result The expression of CAPZA1 was obviously decreased in NSCLC tissues compared with that in adjacent normal tissues(P<0.01). There were no evident differences of CAPZA1 expression level among patients of different gender, age, smoking status, tumor size, or pathological type(P>0.05). The expression level of CAPZA1 was statistically associated with TNM stage, degree of differentiation,lymph node metastases, vascular invasion, and Ki-67 index, and the differences were statistically significant(P<0.05).The Log-rank test indicated that, better survival was observed in patients with high expression level of CAPZA1 compared with those with low CAPZA1 expression(P<0.05). Conclusion The expression of CAPZA1 is reduced in NSCLC tissues, and it is clinically valuable for evaluating the pathological features and prognosis of NSCLC patients.
引文
[1]李勇,张湘茹,孙燕.非小细胞肺癌的化疗进展[J].癌症进展, 2006, 4(4):333-341.
[2]赵宇,郭惠琴.检测非小细胞肺癌患者的血清循环EGFR基因突变研究进展[J].癌症进展, 2012, 10(1):5-9.
[3] Huang D, Cao L, Zheng S. CAPZA1 modulates EMT by regulating actin cytoskeleton remodelling in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2017, 36(1):13.
[4]康南.食管鳞癌来源的P53突变和CAPZA13’UTR高表达的功能研究[D].北京:北京协和医学院;中国医学科学院;清华大学医学部;北京协和医学院中国医学科学院,2014.
[5] Lee YJ, Jeong SH, Hong SC, et al. Prognostic value of CAPZA1 over expression in gastric cancer[J]. Int J Oncol,2013, 42(5):1569-1577.
[6]张树才,王敬慧,农靖颖,等. 2010年非小细胞肺癌NCCN治疗指南解读[J].结核病与胸部肿瘤, 2010(2):148-156.
[7]陆舜,纪文翔,虞永峰. 2014版《NCCN非小细胞肺癌临床实践指南》更新解读[J].中国医师进修杂志, 2015, 38(5):318-320.
[8] Trisal V, Zhou M, Shen B, et al. Over expression of capping protein z line alpha 1(CAPZA 1)and protein phosphatase 1(PP 1)in malignant melanoma as identified by subtractive hybridization[J]. J Clin Oncol, 2004, 22(14_suppl):7518.
[2]赵宇,郭惠琴.检测非小细胞肺癌患者的血清循环EGFR基因突变研究进展[J].癌症进展, 2012, 10(1):5-9.
[3] Huang D, Cao L, Zheng S. CAPZA1 modulates EMT by regulating actin cytoskeleton remodelling in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2017, 36(1):13.
[4]康南.食管鳞癌来源的P53突变和CAPZA13’UTR高表达的功能研究[D].北京:北京协和医学院;中国医学科学院;清华大学医学部;北京协和医学院中国医学科学院,2014.
[5] Lee YJ, Jeong SH, Hong SC, et al. Prognostic value of CAPZA1 over expression in gastric cancer[J]. Int J Oncol,2013, 42(5):1569-1577.
[6]张树才,王敬慧,农靖颖,等. 2010年非小细胞肺癌NCCN治疗指南解读[J].结核病与胸部肿瘤, 2010(2):148-156.
[7]陆舜,纪文翔,虞永峰. 2014版《NCCN非小细胞肺癌临床实践指南》更新解读[J].中国医师进修杂志, 2015, 38(5):318-320.
[8] Trisal V, Zhou M, Shen B, et al. Over expression of capping protein z line alpha 1(CAPZA 1)and protein phosphatase 1(PP 1)in malignant melanoma as identified by subtractive hybridization[J]. J Clin Oncol, 2004, 22(14_suppl):7518.